Want to see SE:MODTX full AI Analyst Report?

Modus Therapeutics Holding AB (MODTX) Price & Analysis

0 Followers

MODTX Stock Chart & Stats

kr0.30

-kr0.02(-1.23%)

At close: Mar 06 4:00 PM EST

kr0.30

-kr0.02(-1.23%)

Day’s Range― - ―

52-Week Rangekr0.21 - kr0.60

Previous CloseN/A

Volume636.00

Average Volume (3M)1.46M

Market Cap

kr65.29M

Enterprise Valuekr39.62M

Total Cash (Recent Filing)kr12.49M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta2.36

Next Earnings

Nov 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding168,701,800

10 Day Avg. Volume452,967

30 Day Avg. Volume1,457,004

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.14

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Zero DebtA debt-free balance sheet limits interest obligations and refinancing exposure while preserving flexibility to allocate capital toward drug development. This provides a meaningful financial cushion for a clinical-stage company, although it does not eliminate the need to raise funding for ongoing operations.

Improved Equity BaseThe stronger equity base indicates that capital has been raised and the balance sheet has improved from prior periods. More equity can support continued clinical development and reduce immediate solvency pressure, giving the company greater capacity to pursue milestones before needing additional financing.

Focused Therapeutic PipelineA focused development strategy in sickle cell disease and related hematologic conditions can help concentrate research resources, clinical expertise, and capital around defined medical needs. Progress in a specialized pipeline may create strategic value through eventual approval, licensing, or pharmaceutical partnership opportunities.

Bears Say

Pre-revenue Business ModelThe absence of commercial revenue means the company has not yet demonstrated a self-sustaining operating model. Near- and medium-term value remains tied to advancing drug candidates rather than established product demand, making future milestones and financing access central to business continuity.

Persistent Operating LossesLarge recurring operating and net losses show that research and development spending is substantially ahead of current earning capacity. Without a clear sustained narrowing in losses, the company may remain dependent on external capital while it works toward clinical, regulatory, and commercial milestones.

Sustained Cash Burn And Funding DependenceMaterial negative operating and free cash flow indicates that the business is not currently self-funding its development programs. Continued cash consumption increases the importance of future equity financing, grants, or partnering transactions and could constrain development plans if funding becomes less available.

MODTX FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was kr0.21 and its highest was kr0.60 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is kr65.29M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Nov 24, 2026 which is in 43 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on Aug 26, 2026. The company reported -kr0.034 earnings per share for the quarter.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 168,701,800 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -kr0.034 in its last earnings report. Following the earnings report the stock price went up 10%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in SE:MODTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.